indomethacin/levonorgestrel (BAY98-7443) / Bayer - LARVOL DELTA

The effect of a combined indomethacin and levonorgestrel-releasing intrauterine system on short-term postplacement bleeding profile: a randomized proof-of-concept trial. (PubMed, Am J Obstet Gynecol) - "All 3 doses of indomethacin substantially reduced the number of bleeding and spotting days in the first 90 days after placement of the levonorgestrel-releasing intrauterine system, thus providing proof of concept. Adding indomethacin to the levonorgestrel-releasing intrauterine system can reduce the number of bleeding and spotting days in the initial 90 days postplacement, without affecting the safety profile, and potentially improving patient acceptability and satisfaction."

Journal • Long-acting Reversible Contraceptives • Pain

INDessa: A Study to Compare 3 Doses of a Hormonal Intra-uterine Device Containing Levonorgestrel and Indomethacin With a Hormonal Intra-uterine Device Containing Only Levonorgestrel to Assess the Effect and Safety of the Combined Components (clinicaltrials.gov) - P2; N=177; Completed; Sponsor: Bayer; Active, not recruiting ➔ Completed

Clinical • Trial completion